Detection of <i>TP53</i> mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status
Cases of acute myeloid leukemia with TP53 mutations predicted to have low transcriptional activity showed reduced overall survival. Our results demonstrate limited practical utility of p53 IHC for accurate evaluation of TP53 mutation status because of multifactorial confounders.
Authors
- Scott B. Lovitch (ORCID: https://orcid.org/0000-0001-9013-0105)
- Brianna Waller
- Ashwini Jambhekar (ORCID: https://orcid.org/0000-0003-1078-6601)
- Lee P. Richman (ORCID: https://orcid.org/0000-0002-4601-5190)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Dana-Farber/Harvard Cancer Center (US)
- Center for Systems Biology (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1093/ajcp/aqaf047
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ludwig Center at Harvard